At the start of European Immunization Week, the ECDC report “Poliomyelitis situation update” reveals that between 2012 and 2021, approximately 2.4 million children in the EU/EEA may have not received three doses of polio-containing vaccines on time. Additionally, the newly published ECDC “Measles Annual Epidemiological Report 2022” highlights the risks when having pockets of an under-vaccinated population or groups not immunised at all.
Since late February 2023 and up until 30 March 2023, 87 cases of botulism linked to intragastric injection of the botulinum neurotoxin (BoNT) have been reported.
Since late February 2023 and as of 10 March 2023, 67 cases of botulism linked to intragastric injection of the botulism neurotoxin (BoNT) have been reported in Germany (12), Austria (1), Switzerland (1) and Türkiye (53).
Immediate health needs following earthquakes in Türkiye and Syria are mostly related to trauma and the disruption of healthcare, however, infectious disease threats may be concerning in the following two to four weeks.
On 11 January 2023, Uganda declared that the Ebola disease outbreak caused by the Sudan ebolavirus was over. The declaration was made after 42 days passed without any case reported, since the last case was released from care.
A number of European countries (including Ireland, France, the Netherlands, Sweden and the United Kingdom) indicate an increase seen during 2022, particularly since September 2022, in the number of cases of invasive Group A Streptococcus (iGAS) disease among children less than ten years of age.
ECDC is actively monitoring the Ebola outbreak in Uganda through its epidemic intelligence activities and regular communication with Africa CDC, WHO (Ebola Disease caused by Sudan virus – Uganda) and GOARN partners.
Globally, as of 9 August, 19 cases of polio due to wild poliovirus type 1 (WPV1) and 223 cases due to circulating vaccine derived poliovirus (cVDPV) have been reported this year. In 2022, the cVDPV cases have been reported in 15 countries, with 93% of the cases attributed to cVDPV type 2 (cVDPV2).